MedKoo Cat#: 562847 | Name: Naratriptan HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Naratriptan is a selective 5-HT1 receptor subtype agonist for the treatment of migraine headache. Naratriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (including substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of AMERGE for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Chemical Structure

Naratriptan HCl
Naratriptan HCl
CAS#143388-64-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 562847

Name: Naratriptan HCl

CAS#: 143388-64-1 (HCl)

Chemical Formula: C17H26ClN3O2S

Exact Mass: 0.0000

Molecular Weight: 371.92

Elemental Analysis: C, 54.90; H, 7.05; Cl, 9.53; N, 11.30; O, 8.60; S, 8.62

Price and Availability

Size Price Availability Quantity
50mg USD 150.00 Ready to ship
100mg USD 250.00 Ready to ship
200mg USD 450.00 Ready to ship
500mg USD 950.00 Ready to ship
1g USD 1,450.00 Ready to ship
2g USD 2,650.00 Ready to ship
5g USD 4,850.00 Ready to ship
10g USD 7,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Naratriptan HCl; Naratriptan Hydrochloride; Amerge; Naramig; GR-85548A; GR 85548A; GR85548A;
IUPAC/Chemical Name
N-Methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide hydrochloride
InChi Key
AWEZYKMQFAUBTD-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H25N3O2S.ClH/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14;/h3-4,11-12,14,18-19H,5-10H2,1-2H3;1H
SMILES Code
CN1CCC(C2=CNC3=C2C=C(CCS(=O)(NC)=O)C=C3)CC1.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2935.90.6000
More Info
Biological target:
5-HT Receptor
In vitro activity:
C appears to promote enhanced membrane permeation of NAR because of its rapid uptake into the buccal tissue. Synergistic enhancement of buccal permeation was observed when TC was combined with MG and this is attributed to the increased thermodynamic activity of NAR in these formulations. Significantly enhanced permeation of NAR was achieved for TC:MG and this was also associated with less TC remaining on the tissue or in the tissue at the end of the experiment. To our knowledge this is the first report where both enhancer and active have been monitored in buccal permeation studies. The findings underline the importance of understanding the fate of vehicle components for rational formulation design of buccal delivery systems. Reference: Sattar M, Lane ME. Oral transmucosal delivery of naratriptan. Int J Pharm. 2016 Nov 30;514(1):263-269. doi: 10.1016/j.ijpharm.2016.06.039. PMID: 27863671.
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 371.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Sattar M, Lane ME. Oral transmucosal delivery of naratriptan. Int J Pharm. 2016 Nov 30;514(1):263-269. doi: 10.1016/j.ijpharm.2016.06.039. PMID: 27863671.
In vitro protocol:
Sattar M, Lane ME. Oral transmucosal delivery of naratriptan. Int J Pharm. 2016 Nov 30;514(1):263-269. doi: 10.1016/j.ijpharm.2016.06.039. PMID: 27863671.
In vivo protocol:
TBD
1: Sattar M, Lane ME. Oral transmucosal delivery of naratriptan. Int J Pharm. 2016 Nov 30;514(1):263-269. doi: 10.1016/j.ijpharm.2016.06.039. PubMed PMID: 27863671. 2: Prajapati PB, Chotalia J, Bodiwala KB, Marolia BP, Shah SA. Development and Validation of Stability-Indicating HPTLC Method for Estimation of Naratriptan Hydrochloride in Its Pharmaceutical Dosage Form and Its Content Uniformity Testing. J Chromatogr Sci. 2016 Aug;54(7):1129-36. doi: 10.1093/chromsci/bmw080. PubMed PMID: 27406125. 3: Sattar M, Hadgraft J, Lane ME. Preparation, characterization and buccal permeation of naratriptan. Int J Pharm. 2015 Sep 30;493(1-2):146-51. doi: 10.1016/j.ijpharm.2015.07.035. Epub 2015 Jul 18. PubMed PMID: 26196276.